HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

Many materials store information about what has happened to them in a sort of material memory, like wrinkles on a once ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Vistagen has reported positive outcomes from the exploratory Phase IIA trial of an investigational pherine nasal spray, PH284, for the treatment of cancer cachexia. The 'previously unreported ...

PH284 is our fifth novel investigational pherine, each supported by positive Phase 2 or later clinical data and placebo-like tolerability, underscoring the breadth, diversity and potential of our ...

--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified ...

Cocrystal Pharma announced positive interim results from a Phase 1 study of its oral pan-viral protease inhibitor CDI-988, designed for the treatment of norovirus and coronavirus infections.

The single arm pivotal Phase 2 trials will study the drug combination ... In CRC pre-clinical studies, THIO administered in sequence with a CPI resulted in 100% complete response and anticancer ...

Launched on December 30, 2024, the SpaDeX satellites are currently engaged in a carefully orchestrated sequence to close the distance between them. Listen to Story Initially separated by approximately ...

Testing positive for COVID-19 is not exactly a positive experience. After all, wanting to go viral these days doesn’t tend to mean wanting to be infected by the severe acute respiratory syndrome ...

Division of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan The HAKUBI Center for Advanced Research, Kyoto University, ...